» Articles » PMID: 10655057

Aberrant CpG-island Methylation Has Non-random and Tumour-type-specific Patterns

Abstract

CpG islands frequently contain gene promoters or exons and are usually unmethylated in normal cells. Methylation of CpG islands is associated with delayed replication, condensed chromatin and inhibition of transcription initiation. The investigation of aberrant CpG-island methylation in human cancer has primarily taken a candidate gene approach, and has focused on less than 15 of the estimated 45,000 CpG islands in the genome. Here we report a global analysis of the methylation status of 1,184 unselected CpG islands in each of 98 primary human tumours using restriction landmark genomic scanning (RLGS). We estimate that an average of 600 CpG islands (range of 0 to 4,500) of the 45,000 in the genome were aberrantly methylated in the tumours, including early stage tumours. We identified patterns of CpG-island methylation that were shared within each tumour type, together with patterns and targets that displayed distinct tumour-type specificity. The expression of many of these genes was reactivated by experimental demethylation in cultured tumour cells. Thus, the methylation of particular subsets of CpG islands may have consequences for specific tumour types.

Citing Articles

Profiling the epigenome using long-read sequencing.

Liu T, Conesa A Nat Genet. 2025; 57(1):27-41.

PMID: 39779955 DOI: 10.1038/s41588-024-02038-5.


Development and validation of the utLIFE-PC algorithm for noninvasive detection of prostate cancer in urine: A prospective, observational study.

Han S, Wang M, Wang Y, Wu J, Guo Z, Wang H Cell Rep Med. 2024; 5(12):101870.

PMID: 39657665 PMC: 11722088. DOI: 10.1016/j.xcrm.2024.101870.


Genome-wide DNA methylation profiling reveals a novel hypermethylated biomarker PRKCB in gastric cancer.

Li L, Fei X, Wang H, Chen S, Xu X, Ke H Sci Rep. 2024; 14(1):26605.

PMID: 39496833 PMC: 11535215. DOI: 10.1038/s41598-024-78135-6.


Insights into the regulatory role of epigenetics in moyamoya disease: Current advances and future prospectives.

Xu S, Chen T, Yu J, Wan L, Zhang J, Chen J Mol Ther Nucleic Acids. 2024; 35(3):102281.

PMID: 39188306 PMC: 11345382. DOI: 10.1016/j.omtn.2024.102281.


Unravelling the mosaic: Epigenetic diversity in glioblastoma.

Lucchini S, Constantinou M, Marino S Mol Oncol. 2024; 18(12):2871-2889.

PMID: 39148319 PMC: 11619803. DOI: 10.1002/1878-0261.13706.